This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Kivexa - API Insight, 2019-2021: Historical & Forecasted Sales, Emerging Therapies and Key Opportunities - ResearchAndMarkets.com

March 13, 2019

DUBLIN--(BUSINESS WIRE)--Mar 13, 2019--The “Kivexa - API Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Kivexa - API Insight, 2019 provides product and API manufacturers’ details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to Kivexa. The report also highlights the patent details of Kivexa.

Scope of the Report

  • A comprehensive product overview including product description, regulatory milestones, safety, pharmacological properties, clinical trials, and product development activities have been elaborated in this report
  • Patent information around Kivexa in United States (US) and Europe (EU) has been highlighted
  • API manufacturers for Kivexa in United States, Europe, China and India
  • The report contains historical and forecasted sales for Kivexa till 2021
  • Enlists the market competition and emerging therapies in the space where Kivexa operates

Reasons to Buy

  • Evaluate the marketing status of Kivexa to exploit opportunities for generic Kivexa development opportunities
  • Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details with respect to Kivexa
  • API intelligence over Kivexa and gaining primary intelligence over Active Ingredient manufacturers by country
  • Make more informed business decisions from insightful and in-depth analysis of Kivexa’s performance

Topics Covered

1. Kivexa Overview

2. Kivexa Global Sales Assessment

  • Kivexa Historical Global Sales
  • Kivexa Forecasted Global Sales

3. Product Description

  • Mechanism of Action
  • Pharmacodynamic Properties
  • Pharmacokinetic Properties

4. Product Details by Country

5. Patent Information

6. Global API Manufacturers Assessment

  • Active Pharmaceutical Ingredient (API) Manufacturers by Country
  • Active Pharmaceutical Ingredient (API) Manufacturers by Region

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/4hl2km/kivexa_api?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190313005313/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Diseases Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 03/13/2019 06:11 AM/DISC: 03/13/2019 06:11 AM